LEIDEN, NETHERLANDS--(Marketwire - March 07, 2011) - Pharming Group NV ("Pharming" or "the
Company") (NYSE Euronext: PHARM) today announced that Socius CG II, Ltd, a
subsidiary of Socius Capital Group, LLC ("Socius"), based in New York and
Angeles, exercised all 24,339,623 warrants under the EUR16.1 million
agreement entered into with Pharming in December 2010.
Under the terms of the agreement, Socius received 24,339,623 warrants with
exercise price of EUR0.212 (21.2 cents), which have now been exercised.
of the exercise takes place through a cash consideration of EUR0.04 per
(EUR973,584.92) and issuance of a Promissory Note for the remaining
As of December 31, 2010, Pharming had 436,261,010 shares outstanding. The
number of outstanding shares is 461,116,470 comprising the previous balance
including the exercise of the warrants by Socius (24,339,623) and shares
(515,837) issued as part consideration of bonus payments to Pharming staff.
About Pharming Group NV
Pharming Group NV is developing innovative products for the treatment of
medical needs. Ruconest™ (Rhucin® in non-European territories) is a
recombinant human C1 inhibitor approved for the treatment of angioedema
in patients with HAE in all 27 EU countries plus Norway, Iceland and
Liechtenstein. The product is also under development for follow-on
i.e. antibody-mediated rejection (AMR) and delayed graft function (DGF)
following kidney transplantation. The advanced technologies of the Company
include innovative platforms for the production of protein therapeutics,
technology and processes for the purification and formulation of these
Additional information is available on the Pharming
This press release contains forward looking statements that involve known
unknown risks, uncertainties and other factors, which may cause the actual
results, performance or achievements of the Company to be materially
from the results, performance or achievements expressed or implied by these
forward looking statements.
Press release (PDF):
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Pharming Group N.V. via Thomson Reuters ONE